Intratracheal instillation of alveolar type II cells enhances recovery from acute lung injury in rats

Journal of Heart and Lung Transplantation

Volumn 37, Issue 6, 2018, Pages 782-791

  Guillamat Prats, Raquel ^a,b   Puig, Ferranda ^a,b   Camprubí Rimblas, Marta ^a,b,c   Herrero, Raquel ^a,d   Serrano Mollar, Anna ^a,e   Gómez, Maria Nieves ^b   Tijero, Jessica ^b   Matthay, Michael A ^f,g   Blanch, Lluís ^a,b,c,h   Artigas, Antonio ^a,b,c,h  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^e INST D INVESTIGACIONS B   (Spain)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Critical Care Center   (Spain)

Author keywords

acute lung injury; acute respiratory distress syndrome; alveolar type II cells; cell therapy; macrophages

Indexed keywords

HYDROCHLORIC ACID; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; SURFACTANT PROTEIN A;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL TRANSPLANTATION; CONTROLLED STUDY; FIBROBLAST; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; MALE; MORTALITY; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; RAT; ANIMAL; CLASSIFICATION; LUNG ALVEOLUS EPITHELIUM CELL; PROCEDURES; REMISSION; SPRAGUE DAWLEY RAT; TRACHEA; TRANSPLANTATION;

ACUTE LUNG INJURY; ALVEOLAR EPITHELIAL CELLS; ANIMALS; CELL TRANSPLANTATION; MALE; RATS; RATS, SPRAGUE-DAWLEY; REMISSION INDUCTION; TRACHEA;

EID: 85044636119     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2017.10.025     Document Type: Article

References (41)

1. Bellani, G., Pham, T., Laffey, J., LUNG-SAFE Investigators, ESICM Trials Group. Incidence of acute respiratory distress syndrome—Reply. JAMA, 316, 2016, 347.
2. Bellani, G., Laffey, J.G., Pham, T., et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE Study. Am J Respir Crit Care Med 195 (2017), 67–77.
3. Slutsky, A.S., Ranieri, V.M., Mechanical ventilation: lessons from the ARDSNet trial. Respir Res 1 (2000), 73–77.
4. Guerin, C., Baboi, L., Richard, J.C., Mechanisms of the effects of prone positioning in acute respiratory distress syndrome. Intensive Care Med 40 (2014), 1634–1642.
5. Papazian, L., Forel, J.-M., Gacouin, A., et al. Neuromuscular blockers in early acute respiratory distress syndrome. New Engl J Med 363 (2010), 1107–1116.
6. Jacobson, J.R., Barnard, J.W., Grigoryev, D.N., et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288 (2005), L1026–L1032.
7. Zarbock, A., Singbartl, K., Ley, K., Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116 (2006), 3211–3219.
8. Wang, Y., Wang, F., Yang, D., et al. Berberine in combination with yohimbine attenuates sepsis-induced neutrophil tissue infiltration and multiorgan dysfunction partly via IL-10-mediated inhibition of CCR2 expression in neutrophils. Int Immunopharmacol 35 (2016), 217–225.
9. Lai, K.N., Leung, J.C.K., Metz, C.N., et al. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol 199 (2003), 496–508.
10. Neville, L.F., Abdullah, F., McDonnell, P.M., et al. Mob-1 expression in IL-2-induced ARDS: regulation by TNF-alpha. Am J Physiol 269 (1995), L884–L890.
11. Spieth, P.M., Zhang, H., Pharmacological therapies for acute respiratory distress syndrome. Curr Opin Crit Care 20 (2014), 113–121.
12. Bhargava, R., Janssen, W., Altmann, C., et al. Intratracheal IL-6 protects against lung inflammation in direct, but not indirect, causes of acute lung injury in mice. PloS One, 8, 2013, e61405.
13. Park, W.Y., Goodman, R.B., Steinberg, K.P., et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 164 (2001), 1896–1903.
14. Armstrong, L., Millar, A.B., Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome. Thorax 52 (1997), 442–446.
15. Matthay, M.A., Goolaerts, A., Howard, J.P., et al. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med 38:suppl (2010), S569–S573.
16. Mao, P., Wu, S., Li, J., et al. Human alveolar epithelial type II cells in primary culture. Physiol Rep, 3, 2015.
17. Herzog, E.L., Brody, A.R., Colby, T.V., et al. Knowns and unknowns of the alveolus. Proc Am Thorac Soc 5 (2008), 778–782.
18. Fehrenbach, H., Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2 (2001), 33–46.
19. Pison, U., Brand, M., Joka, T., et al. Distribution and function of alveolar cells in multiply injured patients with trauma-induced ARDS. Intensive Care Med 14 (1988), 602–609.
20. Serrano-Mollar, A., Nacher, M., Gay-Jordi, G., et al. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 176 (2007), 1261–1268.
21. Guillamat-Prats, R., Gay-Jordi, G., Xaubet, A., et al. Alveolar type II cell transplantation restores pulmonary surfactant protein levels in lung fibrosis. J Heart Lung Transplant 33 (2014), 758–765.
22. Serrano-Mollar, A., Gay-Jordi, G., Guillamat-Prats, R., et al. Safety and tolerability of alveolar type II cell transplantation in idiopathic pulmonary fibrosis. Chest 150 (2016), 533–543.
23. Lo, B., Hansen, S., Evans, K., et al. Alveolar epithelial type II cells induce T cell tolerance to specific antigen. J Immunol 180 (2008), 881–888.
24. Lopez-Rodriguez, E., Gay-Jordi, G., Mucci, A., et al. Lung surfactant metabolism: early in life, early in disease and target in cell therapy. Cell Tissue Res 367 (2017), 721–735.
25. Gordon, S., Martinez, F.O., Alternative activation of macrophages: mechanism and functions. Immunity 32 (2010), 593–604.
26. Martinez, F.O., Sica, A., Mantovani, A., et al. Macrophage activation and polarization. Front Biosci J Virtual Libr 13 (2008), 453–461.
27. Sica, A., Mantovani, A., Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122 (2012), 787–795.
28. Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8 (2008), 958–969.
29. Puig, F., Herrero, R., Guillamat-Prats, R., et al. A new experimental model of acid and endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 311 (2016), L229–L237.
30. Speth, J.M., Bourdonnay, E., Penke, L.R.K., et al. Alveolar epithelial cell-derived prostaglandin E2 serves as a request signal for macrophage secretion of suppressor of cytokine signaling 3 during innate inflammation. J Immunol 196 (2016), 5112–5120.
31. Bourdonnay, E., Zasłona, Z., Penke, L.R.K., et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J Exp Med 212 (2015), 729–742.
32. Aronoff, D.M., Canetti, C., Peters-Golden, M., Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol 173 (2004), 559–565.
33. Degraaf, A.J., Zasłona, Z., Bourdonnay, E., et al. Prostaglandin E2 reduces Toll-like receptor 4 expression in alveolar macrophages by inhibition of translation. Am J Respir Cell Mol Biol 51 (2014), 242–250.
34. Serezani, C.H., Chung, J., Ballinger, M.N., et al. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol 37 (2007), 562–570.
35. Acarregui, M.J., Snyder, J.M., Mitchell, M.D., et al. Prostaglandins regulate surfactant protein A (SP-A) gene expression in human fetal lung in vitro. Endocrinology 127 (1990), 1105–1113.
36. Morsy, M.A., Isohama, Y., Miyata, T., Prostaglandin E(2) increases surfactant secretion via the EP(1) receptor in rat alveolar type II cells. Eur J Pharmacol 426 (2001), 21–24.
37. Minutti, C.M., García-Fojeda, B., Sáenz, A., et al. Surfactant protein A prevents IFN-γ/IFN-γ receptor interaction and attenuates classical activation of human alveolar macrophages. J Immunol 197 (2016), 590–598.
38. Minutti, C.M., Jackson-Jones, L.H., García-Fojeda, B., et al. Local amplifiers of IL-4Rα-mediated macrophage activation promote repair in lung and liver. Science 356 (2017), 1076–1080.
39. Goto, H., Ledford, J.G., Mukherjee, S., et al. The role of surfactant protein A in bleomycin-induced acute lung injury. Am J Respir Crit Care Med 181 (2010), 1336–1344.
40. Németh, K., Leelahavanichkul, A., Yuen, P.S.T., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15 (2009), 42–49.
41. Matthay, M.A., Ware, L.B., Zimmerman, G.A., The acute respiratory distress syndrome. J Clin Invest 122 (2012), 2731–2740.